Nurix Therapeutics, Inc. (NRIX) financial statements (2022 and earlier)

Company profile

Business Address 1700 OWENS STREET, SUITE 205
SAN FRANCISCO, CA 94158
State of Incorp. DE
Fiscal Year End November 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

11/30/2021
11/30/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:295,700281,148
Cash and cash equivalents80,506119,356
Short-term investments215,214161,792
Other undisclosed cash, cash equivalents, and short-term investments(20) 
Receivables6,0003,900
Deferred costs500 
Other undisclosed current assets8,91813,386
Total current assets:311,118298,434
Noncurrent Assets
Operating lease, right-of-use asset14,005 
Property, plant and equipment11,3406,672
Long-term investments and receivables137,18990,890
Long-term investments137,18990,890
Restricted cash and investments286170
Other noncurrent assets2,833177
Total noncurrent assets:165,65397,909
TOTAL ASSETS:476,771396,343
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,3829,802
Accounts payable6,6503,412
Accrued liabilities803591
Employee-related liabilities8,8545,725
Taxes payable7574
Deferred revenue41,21232,799
Other liabilities659700
Other undisclosed current liabilities8,0051,238
Total current liabilities:66,25844,539
Noncurrent Liabilities
Long-term debt and lease obligation9,189 
Operating lease, liability9,189 
Liabilities, other than long-term debt59,02261,535
Deferred revenue59,02260,685
Other liabilities 850
Total noncurrent liabilities:68,21161,535
Total liabilities:134,469106,074
Stockholders' equity
Stockholders' equity attributable to parent342,302290,269
Common stock4539
Additional paid in capital563,757393,841
Accumulated other comprehensive income (loss)(608)87
Accumulated deficit(220,892)(103,698)
Total stockholders' equity:342,302290,269
TOTAL LIABILITIES AND EQUITY:476,771396,343

Income statement (P&L) ($ in thousands)

11/30/2021
11/30/2020
Revenues29,75017,820
Gross profit:29,75017,820
Operating expenses(147,636)(82,803)
Operating loss:(117,886)(64,983)
Loss from continuing operations before equity method investments, income taxes:(117,886)(64,983)
Other undisclosed income from continuing operations before income taxes8231,206
Loss from continuing operations before income taxes:(117,063)(63,777)
Income tax expense (benefit)(131)20,535
Net loss available to common stockholders, diluted:(117,194)(43,242)

Comprehensive Income ($ in thousands)

11/30/2021
11/30/2020
Net loss:(117,194)(43,242)
Comprehensive loss:(117,194)(43,242)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(695)89
Comprehensive loss, net of tax, attributable to parent:(117,889)(43,153)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: